Evidence map›Paper›PMID 35346265›Full record

ArticleSubstance abuse treatment, prevention, and policy2022

Barriers of linkage to HCV viremia testing among people who inject drugs in Georgia.

Maia Butsashvili, Tinatin Abzianidze, George Kamkamidze, Lasha Gulbiani, Lia Gvinjilia, Tinatin Kuchuloria, Irina Tskhomelidze, Maka Gogia, Maia Tsereteli, Veronique Miollany and 4 more

Abstract read
In one paragraph

Article in Substance abuse treatment, prevention, and policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Toward reaching hepatitis B goals: hepatitis B epidemiology and the impact of two decades of vaccination, Georgia, 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023
    Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maia ButsashviliHealth Research Union/Clinic NEOLAB, 8 Nutsubidze str., 0177, Tbilisi, Georgia. butsashvilimaia@gmail.com.ORCID 0000-0002-6554-1567
Tinatin AbzianidzeHealth Research Union/Clinic NEOLAB, 8 Nutsubidze str., 0177, Tbilisi, Georgia.
George KamkamidzeHealth Research Union/Clinic NEOLAB, 8 Nutsubidze str., 0177, Tbilisi, Georgia.
Lasha GulbianiHealth Research Union/Clinic NEOLAB, 8 Nutsubidze str., 0177, Tbilisi, Georgia.
Lia GvinjiliaTEPHINET, 9 Asatiani street, 0177, Tbilisi, Georgia.
Tinatin KuchuloriaTEPHINET, 9 Asatiani street, 0177, Tbilisi, Georgia.
Irina TskhomelidzeTEPHINET, 9 Asatiani street, 0177, Tbilisi, Georgia.
Maka GogiaGeorgian Harm Reduction Network, 24 Shartava str. 3rd floor, apt 6, Tbilisi, Georgia.
Maia TsereteliNational Center for Disease Control and Public Health, 99 Kakheti highway, 0198, Tbilisi, Georgia.
Veronique MiollanyMedecins Du Monde, 24 Paliashvili str., 0179, Tbilisi, Georgia.
Tamar KikvidzeMedecins Du Monde, 24 Paliashvili str., 0179, Tbilisi, Georgia.
Shaun ShadakerDivision of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC, 1600 Clifton Road, Atlanta, GA, 30329-4027, USA.
Muazzam NasrullahDivision of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC, 1600 Clifton Road, Atlanta, GA, 30329-4027, USA.
Francisco AverhoffDivision of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC, 1600 Clifton Road, Atlanta, GA, 30329-4027, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeople who inject drugs (PWID) in Georgia have a high prevalence of hepatitis C virus antibody (anti-HCV). Access to care among PWID could be prioritized to meet the country's hepatitis C elimination goals. This study assesses barriers of linkage to HCV viremia testing among PWID in Georgia.

methodsStudy participants were enrolled from 13 harm reduction (HR) centers throughout Georgia. Anti-HCV positive PWID who were tested for viremia (complete diagnosis [CD]), were compared to those not tested for viremia within 90 days of screening anti-HCV positive (not complete diagnosis [NCD]). Convenience samples of CD and NCD individuals recorded at HR centers using beneficiaries' national ID were drawn from the National HCV Elimination Program database. Participants were interviewed about potential barriers to seeking care.

resultsA total of 500 PWID were enrolled, 245 CD and 255 NCD. CD and NCD were similar with respect to gender, age, employment status, education, knowledge of anti-HCV status, and confidence/trust in the elimination program (p > 0.05). More NCD (13.0%) than CD (7.4%) stated they were not sufficiently informed what to do after screening anti-HCV positive (p < 0.05). In multivariate analysis, HCV viremia testing was associated with perceived affordability of the elimination program (adjusted prevalence ratio = 8.53; 95% confidence interval: 4.14-17.62).

conclusionsPost testing counselling and making hepatitis C services affordable could help increase HCV viremia testing among PWID in Georgia.

Indexed as

Drug UsersHepatitis CSubstance Abuse, IntravenousGeorgiaHepacivirusHumansViremiaBarriersDiagnosisEliminationHCVPWID

Identifiers

PMID35346265
PMCPMC8962019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.